Trevi Therapeutics to Participate in Upcoming Events
Rhea-AI Summary
Trevi Therapeutics (Nasdaq: TRVI) announced senior management will participate in investor events and an Investor & Analyst Day in April–May 2026. Key appearances include Needham Virtual Healthcare Conference (fireside chat April 13), Raymond James Biotech Symposium (April 14), Oppenheimer Innovation on the Island (April 27–29), and an in-person Analyst Day May 7, 2026 in Midtown New York.
Management attendees include Jennifer Good, President and CEO, and David Hastings, CFO; the Analyst Day will feature key opinion leaders in chronic cough in IPF/ILD and RCC and a virtual webcast option.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – TRVI
On the day this news was published, TRVI declined 2.93%, reflecting a moderate negative market reaction. Argus tracked a trough of -3.1% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $49M from the company's valuation, bringing the market cap to $1.61B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TRVI is up 6.61% while only one tracked peer (LENZ) shows notable upside momentum, with LENZ up about 5.9%. Other close peers show smaller or no moves, suggesting today’s strength is more company-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 17 | Earnings and pipeline | Positive | -4.5% | Year-end 2025 results and Phase 3/2b development plans with long cash runway. |
| Mar 10 | Earnings call date | Neutral | +1.5% | Announcement of March 17 earnings call and webcast registration details. |
| Mar 09 | Clinical FDA alignment | Positive | -12.0% | End-of-Phase 2 FDA alignment and plan for two pivotal Phase 3 trials. |
| Mar 02 | Conference participation | Neutral | +5.5% | Participation in March 2026 healthcare and rare disease conferences. |
| Feb 17 | Conference participation | Neutral | -2.4% | Oppenheimer healthcare conference fireside chat and investor meetings. |
Positive clinical and earnings updates have previously seen mixed or negative next-day reactions, while conference-participation news has produced modest, often positive, moves.
Over the last several months, Trevi has combined clinical, financial, and investor-relations milestones. On Mar 9, 2026, it reported FDA End-of-Phase 2 alignment for IPF-related chronic cough, planning two pivotal Phase 3 trials, yet shares fell afterward. The Mar 17, 2026 year‑end results highlighted a $188.3M cash position and plans for multiple 2026 trials. Several releases, including March and February conference participation and the upcoming May 7 Investor Day, show a consistent effort to increase visibility with investors and the healthcare community.
Market Pulse Summary
This announcement details Trevi’s participation in several April events and a May 7 Investor and Analyst Day from 10:00 a.m. to 12:00 p.m. ET, featuring senior management and key opinion leaders in IPF/ILD and refractory chronic cough. It builds on recent disclosures of FDA alignment for Phase 3 programs and cash runway into 2028. Investors may watch for further detail on Haduvio’s development plans, trial timing, and strategic priorities communicated through these scheduled appearances.
Key Terms
idiopathic pulmonary fibrosis medical
interstitial lung disease medical
refractory chronic cough medical
AI-generated analysis. Not financial advice.
NEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following events.
25th Annual Needham Virtual Healthcare Conference
April 13 – 16, 2026, Virtual
Fireside Chat: April 13, 12:45 p.m. ET
Trevi Representatives: Jennifer Good, President and CEO, and David Hastings, CFO
Raymond James 2026 Biotech Innovation Symposium
April 14, 2026, New York, New York
Trevi Representatives: Jennifer Good, President and CEO, and David Hastings, CFO
Oppenheimer’s 2026 Innovation on the Island
April 27 – 29, 2026, Puerto Rico
Trevi Representative: Jennifer Good, President and CEO
Trevi Therapeutics Investor and Analyst Day
May 7, 2026, Midtown New York, New York
10:00 a.m. to 12:00 p.m. ET
Representatives: Trevi senior management will be joined by key opinion leaders in chronic cough in IPF/ILD and RCC
To register for the in-person event or virtual webcast, click here.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF-related chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.
Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~150,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50
RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.
Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
Jonathan Carlson
Trevi Therapeutics, Inc.
(203) 654 3286
IR@trevitx.com
Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com
